GlassScriptPhysician profile
Sara A Meyer
NPI 1154611291
$1,844.76
in general payments reported to CMS, 2019-2025
28 companies · $496 in 2025
The $496 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $55.06 · 2021: $80.05 · 2022: $181 · 2023: $286 · 2024: $635 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,318.41 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $598.22 | 2023-2025 | Veozah, Myrbetriq |
| Organon LLC | $152.25 | 2021-2025 | Nexplanon, Jada System |
| Coopersurgical, INC. | $113.37 | 2020-2025 | Onetrac Lx, Sos |
| Lilly USA, LLC | $103.98 | 2024 | Zepbound |
| Hologic Sales and Service, LLC | $102.50 | 2021-2024 | Thinprep 2000 Processor, Aptima |
| Sage Therapeutics, LLC | $85.88 | 2023-2025 | Zurzuvae |
| Novo Nordisk INC | $77.82 | 2022-2025 | Wegovy |
| Amgen INC. | $68.30 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $58.97 | 2019-2024 | |
| Pfizer INC. | $47.53 | 2024-2025 | |
| Axonics, INC. | $44.59 | 2022-2024 | Axonics, Bulkamid |
| Exeltis, USA INC. | $36.49 | 2023-2025 | Slynd |
| Sumitomo Pharma America, INC. | $36.10 | 2023-2025 | Myfembree, Gemtesa |
| Merck Sharp & Dohme LLC | $35.39 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.07 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $32.82 | 2019 | |
| Davol INC. | $26.63 | 2025 | Arista |
| Shield Therapeutics INC | $25.66 | 2024 | |
| Ethicon US, LLC | $25.34 | 2024 | Ethicon, Evarrest |
| Daiichi Sankyo INC. | $24.39 | 2020-2021 | |
| Therapeuticsmd, INC. | $23.68 | 2019 | |
| Meditrina | $17.68 | 2022 | |
| Urovant Sciences INC | $15.55 | 2022 | |
| Genzyme Corporation | $15.08 | 2021 | |
| Tactile Systems Technology INC | $14.58 | 2020 | |
| Si-Bone, INC. | $13.99 | 2019 | |
| Conmed Corporation | $12.90 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.